APO Research
Talk to an analyst

APO RESEARCH · REPORT

Microbial Therapeutic Product

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Microbial Therapeutic Product Market Analysis and Forecast 2026-2032

2 January 2026191 pages

Choose your research edition.

Industry ResearchMicrobial Therapeutic Product Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Microbial Therapeutic Product Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Microbial Therapeutic Product Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Microbial Therapeutic Product Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Microbial Therapeutic Product Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Microbial Therapeutic Product market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Microbial Therapeutic Product is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Microbial Therapeutic Product is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Microbial Therapeutic Product is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Microbial Therapeutic Product is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Microbial Therapeutic Product include Novartis, Roche, Eli Lilly and Company, Pfizer, Amgen Inc., Viatris, Sanofi S.A., Novo Nordisk A/S and Merck & Co. Inc., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Microbial Therapeutic Product, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Microbial Therapeutic Product, also provides the revenue of main regions and countries. Of the upcoming market potential for Microbial Therapeutic Product, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Microbial Therapeutic Product revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Microbial Therapeutic Product market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Microbial Therapeutic Product revenue, projected growth trends, production technology, application and end-user industry.

Microbial Therapeutic Product Segment by Company

Novartis

Roche

Eli Lilly and Company

Pfizer

Amgen Inc.

Viatris

Sanofi S.A.

Novo Nordisk A/S

Merck & Co. Inc.

Intas Pharmaceuticals Ltd.

Dr. Reddy’s Laboratories Ltd.

Bristol-Myers Squibb Company

Boehringer Ingelheim

Biocon

Abbot Laboratories

Microbial Therapeutic Product Segment by Type

Single Use Pre-Filled Injection/Injector Pen

Multi-use Injectors

Others

Microbial Therapeutic Product Segment by Application

Oncology

Haematological Disorders

Immunological Disorders

Allergic Diseases

Metabolic Disorders

Infectious Diseases

Others

Microbial Therapeutic Product Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microbial Therapeutic Product market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Microbial Therapeutic Product and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microbial Therapeutic Product.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Microbial Therapeutic Product in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Microbial Therapeutic Product company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Microbial Therapeutic Product revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Microbial Therapeutic Product Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Single Use Pre-Filled Injection/Injector Pen Major Player Table 3. Multi-use Injectors Major Player Table 4. Others Major Player Table 5. Global Microbial Therapeutic Product Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Oncology Major Player Table 7. Haematological Disorders Major Player Table 8. Immunological Disorders Major Player Table 9. Allergic Diseases Major Player Table 10. Metabolic Disorders Major Player Table 11. Infectious Diseases Major Player Table 12. Others Major Player Table 13. Microbial Therapeutic Product Industry Trends Table 14. Microbial Therapeutic Product Industry Drivers Table 15. Microbial Therapeutic Product Industry Opportunities and Challenges Table 16. Microbial Therapeutic Product Industry Restraints Table 17. Global Microbial Therapeutic Product Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 18. Global Microbial Therapeutic Product Market Size by Region (2021-2026) & (US$ Million) Table 19. Global Microbial Therapeutic Product Market Share by Region (2021-2026) Table 20. Global Microbial Therapeutic Product Market Size by Region (2027-2032) & (US$ Million) Table 21. Global Microbial Therapeutic Product Market Share by Region (2027-2032) Table 22. Global Microbial Therapeutic Product Revenue by Players (US$ Million) & (2021-2026) Table 23. Global Microbial Therapeutic Product Revenue Market Share by Players (2021-2026) Table 24. Global Microbial Therapeutic Product Key Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Microbial Therapeutic Product Key Players Headquarters & Area Served Table 26. Global Microbial Therapeutic Product Players, Product Type & Application Table 27. Global Microbial Therapeutic Product Players Establishment Date Table 28. Global Players Market Concentration Ratio (CR5 and HHI) Table 29. Global Microbial Therapeutic Product by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 30. Global Microbial Therapeutic Product Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Microbial Therapeutic Product Revenue by Type (2021-2026) & (US$ Million) Table 32. Global Microbial Therapeutic Product Revenue by Type (2027-2032) & (US$ Million) Table 33. Global Microbial Therapeutic Product Revenue Market Share by Type (2021-2026) Table 34. Global Microbial Therapeutic Product Revenue Market Share by Type (2027-2032) Table 35. Global Microbial Therapeutic Product Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Microbial Therapeutic Product Revenue by Application (2021-2026) & (US$ Million) Table 37. Global Microbial Therapeutic Product Revenue by Application (2027-2032) & (US$ Million) Table 38. Global Microbial Therapeutic Product Revenue Market Share by Application (2021-2026) Table 39. Global Microbial Therapeutic Product Revenue Market Share by Application (2027-2032) Table 40. Novartis Company Information Table 41. Novartis Business Overview Table 42. Novartis Microbial Therapeutic Product Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Novartis Microbial Therapeutic Product Product Portfolio Table 44. Novartis Recent Development Table 45. Roche Company Information Table 46. Roche Business Overview Table 47. Roche Microbial Therapeutic Product Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Roche Microbial Therapeutic Product Product Portfolio Table 49. Roche Recent Development Table 50. Eli Lilly and Company Company Information Table 51. Eli Lilly and Company Business Overview Table 52. Eli Lilly and Company Microbial Therapeutic Product Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Eli Lilly and Company Microbial Therapeutic Product Product Portfolio Table 54. Eli Lilly and Company Recent Development Table 55. Pfizer Company Information Table 56. Pfizer Business Overview Table 57. Pfizer Microbial Therapeutic Product Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Pfizer Microbial Therapeutic Product Product Portfolio Table 59. Pfizer Recent Development Table 60. Amgen Inc. Company Information Table 61. Amgen Inc. Business Overview Table 62. Amgen Inc. Microbial Therapeutic Product Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Amgen Inc. Microbial Therapeutic Product Product Portfolio Table 64. Amgen Inc. Recent Development Table 65. Viatris Company Information Table 66. Viatris Business Overview Table 67. Viatris Microbial Therapeutic Product Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Viatris Microbial Therapeutic Product Product Portfolio Table 69. Viatris Recent Development Table 70. Sanofi S.A. Company Information Table 71. Sanofi S.A. Business Overview Table 72. Sanofi S.A. Microbial Therapeutic Product Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Sanofi S.A. Microbial Therapeutic Product Product Portfolio Table 74. Sanofi S.A. Recent Development Table 75. Novo Nordisk A/S Company Information Table 76. Novo Nordisk A/S Business Overview Table 77. Novo Nordisk A/S Microbial Therapeutic Product Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Novo Nordisk A/S Microbial Therapeutic Product Product Portfolio Table 79. Novo Nordisk A/S Recent Development Table 80. Merck & Co. Inc. Company Information Table 81. Merck & Co. Inc. Business Overview Table 82. Merck & Co. Inc. Microbial Therapeutic Product Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Merck & Co. Inc. Microbial Therapeutic Product Product Portfolio Table 84. Merck & Co. Inc. Recent Development Table 85. Intas Pharmaceuticals Ltd. Company Information Table 86. Intas Pharmaceuticals Ltd. Business Overview Table 87. Intas Pharmaceuticals Ltd. Microbial Therapeutic Product Revenue and Gross Margin (US$ Million) & (2021-2026) Table 88. Intas Pharmaceuticals Ltd. Microbial Therapeutic Product Product Portfolio Table 89. Intas Pharmaceuticals Ltd. Recent Development Table 90. Dr. Reddy’s Laboratories Ltd. Company Information Table 91. Dr. Reddy’s Laboratories Ltd. Business Overview Table 92. Dr. Reddy’s Laboratories Ltd. Microbial Therapeutic Product Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Dr. Reddy’s Laboratories Ltd. Microbial Therapeutic Product Product Portfolio Table 94. Dr. Reddy’s Laboratories Ltd. Recent Development Table 95. Bristol-Myers Squibb Company Company Information Table 96. Bristol-Myers Squibb Company Business Overview Table 97. Bristol-Myers Squibb Company Microbial Therapeutic Product Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Bristol-Myers Squibb Company Microbial Therapeutic Product Product Portfolio Table 99. Bristol-Myers Squibb Company Recent Development Table 100. Boehringer Ingelheim Company Information Table 101. Boehringer Ingelheim Business Overview Table 102. Boehringer Ingelheim Microbial Therapeutic Product Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Boehringer Ingelheim Microbial Therapeutic Product Product Portfolio Table 104. Boehringer Ingelheim Recent Development Table 105. Biocon Company Information Table 106. Biocon Business Overview Table 107. Biocon Microbial Therapeutic Product Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Biocon Microbial Therapeutic Product Product Portfolio Table 109. Biocon Recent Development Table 110. Abbot Laboratories Company Information Table 111. Abbot Laboratories Business Overview Table 112. Abbot Laboratories Microbial Therapeutic Product Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Abbot Laboratories Microbial Therapeutic Product Product Portfolio Table 114. Abbot Laboratories Recent Development Table 115. North America Microbial Therapeutic Product Revenue by Type (2021-2026) & (US$ Million) Table 116. North America Microbial Therapeutic Product Revenue by Type (2027-2032) & (US$ Million) Table 117. North America Microbial Therapeutic Product Revenue by Application (2021-2026) & (US$ Million) Table 118. North America Microbial Therapeutic Product Revenue by Application (2027-2032) & (US$ Million) Table 119. North America Microbial Therapeutic Product Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 120. North America Microbial Therapeutic Product Revenue by Country (2021-2026) & (US$ Million) Table 121. North America Microbial Therapeutic Product Revenue by Country (US$ Million) & (2027-2032) Table 122. Europe Microbial Therapeutic Product Revenue by Type (2021-2026) & (US$ Million) Table 123. Europe Microbial Therapeutic Product Revenue by Type (2027-2032) & (US$ Million) Table 124. Europe Microbial Therapeutic Product Revenue by Application (2021-2026) & (US$ Million) Table 125. Europe Microbial Therapeutic Product Revenue by Application (2027-2032) & (US$ Million) Table 126. Europe Microbial Therapeutic Product Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 127. Europe Microbial Therapeutic Product Revenue by Country (2021-2026) & (US$ Million) Table 128. Europe Microbial Therapeutic Product Revenue by Country (US$ Million) & (2027-2032) Table 129. China Microbial Therapeutic Product Revenue by Type (2021-2026) & (US$ Million) Table 130. China Microbial Therapeutic Product Revenue by Type (2027-2032) & (US$ Million) Table 131. China Microbial Therapeutic Product Revenue by Application (2021-2026) & (US$ Million) Table 132. China Microbial Therapeutic Product Revenue by Application (2027-2032) & (US$ Million) Table 133. Asia Microbial Therapeutic Product Revenue by Type (2021-2026) & (US$ Million) Table 134. Asia Microbial Therapeutic Product Revenue by Type (2027-2032) & (US$ Million) Table 135. Asia Microbial Therapeutic Product Revenue by Application (2021-2026) & (US$ Million) Table 136. Asia Microbial Therapeutic Product Revenue by Application (2027-2032) & (US$ Million) Table 137. Asia Microbial Therapeutic Product Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 138. Asia Microbial Therapeutic Product Revenue by Region (US$ Million) & (2021-2026) Table 139. Asia Microbial Therapeutic Product Revenue by Region (US$ Million) & (2027-2032) Table 140. SAMEA Microbial Therapeutic Product Revenue by Type (2021-2026) & (US$ Million) Table 141. SAMEA Microbial Therapeutic Product Revenue by Type (2027-2032) & (US$ Million) Table 142. SAMEA Microbial Therapeutic Product Revenue by Application (2021-2026) & (US$ Million) Table 143. SAMEA Microbial Therapeutic Product Revenue by Application (2027-2032) & (US$ Million) Table 144. SAMEA Microbial Therapeutic Product Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 145. SAMEA Microbial Therapeutic Product Revenue by Country (2021-2026) & (US$ Million) Table 146. SAMEA Microbial Therapeutic Product Revenue by Country (US$ Million) & (2027-2032) Table 147. Research Programs/Design for This Report Table 148. Authors List of This Report Table 149. Secondary Sources Table 150. Primary Sources List of Figures Figure 1. Microbial Therapeutic Product Image Figure 2. Global Microbial Therapeutic Product Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Microbial Therapeutic Product Market Size Share 2021 VS 2025 VS 2032 Figure 4. Single Use Pre-Filled Injection/Injector Pen Image Figure 5. Multi-use Injectors Image Figure 6. Others Image Figure 7. Global Microbial Therapeutic Product Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Microbial Therapeutic Product Market Size Share 2021 VS 2025 VS 2032 Figure 9. Oncology Image Figure 10. Haematological Disorders Image Figure 11. Immunological Disorders Image Figure 12. Allergic Diseases Image Figure 13. Metabolic Disorders Image Figure 14. Infectious Diseases Image Figure 15. Others Image Figure 16. Global Microbial Therapeutic Product Market Size (US$ Million) & (2021-2032) Figure 17. Global Microbial Therapeutic Product Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global Microbial Therapeutic Product Market Share by Region: 2021 VS 2025 VS 2032 Figure 19. Global Microbial Therapeutic Product Players Revenue Share Top 10 and Top 5 in 2025 Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Microbial Therapeutic Product Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Microbial Therapeutic Product Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Microbial Therapeutic Product Revenue Market Share by Type (2021-2032) Figure 24. Global Microbial Therapeutic Product Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Microbial Therapeutic Product Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 26. Global Microbial Therapeutic Product Revenue Market Share by Application (2021-2032) Figure 27. North America Microbial Therapeutic Product Revenue YoY Growth (2021-2032) & (US$ Million) Figure 28. North America Microbial Therapeutic Product Revenue Share by Type (2021-2032) Figure 29. North America Microbial Therapeutic Product Revenue Share by Application (2021-2032) Figure 30. North America Microbial Therapeutic Product Revenue Share by Country (2021-2032) Figure 31. United States Microbial Therapeutic Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Canada Microbial Therapeutic Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Mexico Microbial Therapeutic Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Europe Microbial Therapeutic Product Revenue YoY Growth (2021-2032) & (US$ Million) Figure 35. Europe Microbial Therapeutic Product Revenue Share by Type (2021-2032) Figure 36. Europe Microbial Therapeutic Product Revenue Share by Application (2021-2032) Figure 37. Europe Microbial Therapeutic Product Revenue Share by Country (2021-2032) Figure 38. Germany Microbial Therapeutic Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. France Microbial Therapeutic Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. U.K. Microbial Therapeutic Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Italy Microbial Therapeutic Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Spain Microbial Therapeutic Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Russia Microbial Therapeutic Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Netherlands Microbial Therapeutic Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Nordic Countries Microbial Therapeutic Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. China Microbial Therapeutic Product Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. China Microbial Therapeutic Product Revenue Share by Type (2021-2032) Figure 48. China Microbial Therapeutic Product Revenue Share by Application (2021-2032) Figure 49. Asia Microbial Therapeutic Product Revenue YoY Growth (2021-2032) & (US$ Million) Figure 50. Asia Microbial Therapeutic Product Revenue Share by Type (2021-2032) Figure 51. Asia Microbial Therapeutic Product Revenue Share by Application (2021-2032) Figure 52. Asia Microbial Therapeutic Product Revenue Share by Region (2021-2032) Figure 53. Japan Microbial Therapeutic Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. South Korea Microbial Therapeutic Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. India Microbial Therapeutic Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Australia Microbial Therapeutic Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Taiwan Microbial Therapeutic Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Southeast Asia Microbial Therapeutic Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. SAMEA Microbial Therapeutic Product Revenue YoY Growth (2021-2032) & (US$ Million) Figure 60. SAMEA Microbial Therapeutic Product Revenue Share by Type (2021-2032) Figure 61. SAMEA Microbial Therapeutic Product Revenue Share by Application (2021-2032) Figure 62. SAMEA Microbial Therapeutic Product Revenue Share by Country (2021-2032) Figure 63. Brazil Microbial Therapeutic Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Argentina Microbial Therapeutic Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Chile Microbial Therapeutic Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Colombia Microbial Therapeutic Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Peru Microbial Therapeutic Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Saudi Arabia Microbial Therapeutic Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Israel Microbial Therapeutic Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. UAE Microbial Therapeutic Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Turkey Microbial Therapeutic Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Iran Microbial Therapeutic Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Egypt Microbial Therapeutic Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Single Use Pre-Filled Injection/Injector Pen
  • Multi-use Injectors
  • Others
Applications
  • Oncology
  • Haematological Disorders
  • Immunological Disorders
  • Allergic Diseases
  • Metabolic Disorders
  • Infectious Diseases
  • Others
Companies covered
  • Novartis
  • Roche
  • Eli Lilly and Company
  • Pfizer
  • Amgen Inc.
  • Viatris
  • Sanofi S.A.
  • Novo Nordisk A/S
  • Merck & Co. Inc.
  • Intas Pharmaceuticals Ltd.
  • Dr. Reddy’s Laboratories Ltd.
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim
  • Biocon
  • Abbot Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Microbial Therapeutic Product Market by Type
  3. 1.2.1 Global Microbial Therapeutic Product Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Single Use Pre-Filled Injection/Injector Pen
  5. 1.2.3 Multi-use Injectors
  6. 1.2.4 Others
  7. 1.3 Microbial Therapeutic Product Market by Application
  8. 1.3.1 Global Microbial Therapeutic Product Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Oncology
  10. 1.3.3 Haematological Disorders
  11. 1.3.4 Immunological Disorders
  12. 1.3.5 Allergic Diseases
  13. 1.3.6 Metabolic Disorders
  14. 1.3.7 Infectious Diseases
  15. 1.3.8 Others
  16. 1.4 Assumptions and Limitations
  17. 1.5 Study Goals and Objectives
2 Microbial Therapeutic Product Market Dynamics
  1. 2.1 Microbial Therapeutic Product Industry Trends
  2. 2.2 Microbial Therapeutic Product Industry Drivers
  3. 2.3 Microbial Therapeutic Product Industry Opportunities and Challenges
  4. 2.4 Microbial Therapeutic Product Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Microbial Therapeutic Product Market Perspective (2021-2032)
  2. 3.2 Global Microbial Therapeutic Product Growth Trends by Region
  3. 3.2.1 Global Microbial Therapeutic Product Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Microbial Therapeutic Product Market Size by Region (2021-2026)
  5. 3.2.3 Global Microbial Therapeutic Product Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Microbial Therapeutic Product Revenue by Players
  2. 4.1.1 Global Microbial Therapeutic Product Revenue by Players (2021-2026)
  3. 4.1.2 Global Microbial Therapeutic Product Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Microbial Therapeutic Product Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Microbial Therapeutic Product Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Microbial Therapeutic Product Key Players Headquarters & Area Served
  7. 4.4 Global Microbial Therapeutic Product Players, Product Type & Application
  8. 4.5 Global Microbial Therapeutic Product Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Microbial Therapeutic Product Market CR5 and HHI
  11. 4.6.3 2025 Microbial Therapeutic Product Tier 1, Tier 2, and Tier 3
5 Microbial Therapeutic Product Market Size by Type
  1. 5.1 Global Microbial Therapeutic Product Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Microbial Therapeutic Product Revenue by Type (2021-2032)
  3. 5.3 Global Microbial Therapeutic Product Revenue Market Share by Type (2021-2032)
6 Microbial Therapeutic Product Market Size by Application
  1. 6.1 Global Microbial Therapeutic Product Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Microbial Therapeutic Product Revenue by Application (2021-2032)
  3. 6.3 Global Microbial Therapeutic Product Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Novartis
  2. 7.1.1 Novartis Company Information
  3. 7.1.2 Novartis Business Overview
  4. 7.1.3 Novartis Microbial Therapeutic Product Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Novartis Microbial Therapeutic Product Product Portfolio
  6. 7.1.5 Novartis Recent Developments
  7. 7.2 Roche
  8. 7.2.1 Roche Company Information
  9. 7.2.2 Roche Business Overview
  10. 7.2.3 Roche Microbial Therapeutic Product Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Roche Microbial Therapeutic Product Product Portfolio
  12. 7.2.5 Roche Recent Developments
  13. 7.3 Eli Lilly and Company
  14. 7.3.1 Eli Lilly and Company Company Information
  15. 7.3.2 Eli Lilly and Company Business Overview
  16. 7.3.3 Eli Lilly and Company Microbial Therapeutic Product Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Eli Lilly and Company Microbial Therapeutic Product Product Portfolio
  18. 7.3.5 Eli Lilly and Company Recent Developments
  19. 7.4 Pfizer
  20. 7.4.1 Pfizer Company Information
  21. 7.4.2 Pfizer Business Overview
  22. 7.4.3 Pfizer Microbial Therapeutic Product Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Pfizer Microbial Therapeutic Product Product Portfolio
  24. 7.4.5 Pfizer Recent Developments
  25. 7.5 Amgen Inc.
  26. 7.5.1 Amgen Inc. Company Information
  27. 7.5.2 Amgen Inc. Business Overview
  28. 7.5.3 Amgen Inc. Microbial Therapeutic Product Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Amgen Inc. Microbial Therapeutic Product Product Portfolio
  30. 7.5.5 Amgen Inc. Recent Developments
  31. 7.6 Viatris
  32. 7.6.1 Viatris Company Information
  33. 7.6.2 Viatris Business Overview
  34. 7.6.3 Viatris Microbial Therapeutic Product Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Viatris Microbial Therapeutic Product Product Portfolio
  36. 7.6.5 Viatris Recent Developments
  37. 7.7 Sanofi S.A.
  38. 7.7.1 Sanofi S.A. Company Information
  39. 7.7.2 Sanofi S.A. Business Overview
  40. 7.7.3 Sanofi S.A. Microbial Therapeutic Product Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Sanofi S.A. Microbial Therapeutic Product Product Portfolio
  42. 7.7.5 Sanofi S.A. Recent Developments
  43. 7.8 Novo Nordisk A/S
  44. 7.8.1 Novo Nordisk A/S Company Information
  45. 7.8.2 Novo Nordisk A/S Business Overview
  46. 7.8.3 Novo Nordisk A/S Microbial Therapeutic Product Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Novo Nordisk A/S Microbial Therapeutic Product Product Portfolio
  48. 7.8.5 Novo Nordisk A/S Recent Developments
  49. 7.9 Merck & Co. Inc.
  50. 7.9.1 Merck & Co. Inc. Company Information
  51. 7.9.2 Merck & Co. Inc. Business Overview
  52. 7.9.3 Merck & Co. Inc. Microbial Therapeutic Product Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Merck & Co. Inc. Microbial Therapeutic Product Product Portfolio
  54. 7.9.5 Merck & Co. Inc. Recent Developments
  55. 7.10 Intas Pharmaceuticals Ltd.
  56. 7.10.1 Intas Pharmaceuticals Ltd. Company Information
  57. 7.10.2 Intas Pharmaceuticals Ltd. Business Overview
  58. 7.10.3 Intas Pharmaceuticals Ltd. Microbial Therapeutic Product Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Intas Pharmaceuticals Ltd. Microbial Therapeutic Product Product Portfolio
  60. 7.10.5 Intas Pharmaceuticals Ltd. Recent Developments
  61. 7.11 Dr. Reddy’s Laboratories Ltd.
  62. 7.11.1 Dr. Reddy’s Laboratories Ltd. Company Information
  63. 7.11.2 Dr. Reddy’s Laboratories Ltd. Business Overview
  64. 7.11.3 Dr. Reddy’s Laboratories Ltd. Microbial Therapeutic Product Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Dr. Reddy’s Laboratories Ltd. Microbial Therapeutic Product Product Portfolio
  66. 7.11.5 Dr. Reddy’s Laboratories Ltd. Recent Developments
  67. 7.12 Bristol-Myers Squibb Company
  68. 7.12.1 Bristol-Myers Squibb Company Company Information
  69. 7.12.2 Bristol-Myers Squibb Company Business Overview
  70. 7.12.3 Bristol-Myers Squibb Company Microbial Therapeutic Product Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Bristol-Myers Squibb Company Microbial Therapeutic Product Product Portfolio
  72. 7.12.5 Bristol-Myers Squibb Company Recent Developments
  73. 7.13 Boehringer Ingelheim
  74. 7.13.1 Boehringer Ingelheim Company Information
  75. 7.13.2 Boehringer Ingelheim Business Overview
  76. 7.13.3 Boehringer Ingelheim Microbial Therapeutic Product Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Boehringer Ingelheim Microbial Therapeutic Product Product Portfolio
  78. 7.13.5 Boehringer Ingelheim Recent Developments
  79. 7.14 Biocon
  80. 7.14.1 Biocon Company Information
  81. 7.14.2 Biocon Business Overview
  82. 7.14.3 Biocon Microbial Therapeutic Product Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Biocon Microbial Therapeutic Product Product Portfolio
  84. 7.14.5 Biocon Recent Developments
  85. 7.15 Abbot Laboratories
  86. 7.15.1 Abbot Laboratories Company Information
  87. 7.15.2 Abbot Laboratories Business Overview
  88. 7.15.3 Abbot Laboratories Microbial Therapeutic Product Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Abbot Laboratories Microbial Therapeutic Product Product Portfolio
  90. 7.15.5 Abbot Laboratories Recent Developments
8 North America
  1. 8.1 North America Microbial Therapeutic Product Revenue (2021-2032)
  2. 8.2 North America Microbial Therapeutic Product Revenue by Type (2021-2032)
  3. 8.2.1 North America Microbial Therapeutic Product Revenue by Type (2021-2026)
  4. 8.2.2 North America Microbial Therapeutic Product Revenue by Type (2027-2032)
  5. 8.3 North America Microbial Therapeutic Product Revenue Share by Type (2021-2032)
  6. 8.4 North America Microbial Therapeutic Product Revenue by Application (2021-2032)
  7. 8.4.1 North America Microbial Therapeutic Product Revenue by Application (2021-2026)
  8. 8.4.2 North America Microbial Therapeutic Product Revenue by Application (2027-2032)
  9. 8.5 North America Microbial Therapeutic Product Revenue Share by Application (2021-2032)
  10. 8.6 North America Microbial Therapeutic Product Revenue by Country
  11. 8.6.1 North America Microbial Therapeutic Product Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Microbial Therapeutic Product Revenue by Country (2021-2026)
  13. 8.6.3 North America Microbial Therapeutic Product Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Microbial Therapeutic Product Revenue (2021-2032)
  2. 9.2 Europe Microbial Therapeutic Product Revenue by Type (2021-2032)
  3. 9.2.1 Europe Microbial Therapeutic Product Revenue by Type (2021-2026)
  4. 9.2.2 Europe Microbial Therapeutic Product Revenue by Type (2027-2032)
  5. 9.3 Europe Microbial Therapeutic Product Revenue Share by Type (2021-2032)
  6. 9.4 Europe Microbial Therapeutic Product Revenue by Application (2021-2032)
  7. 9.4.1 Europe Microbial Therapeutic Product Revenue by Application (2021-2026)
  8. 9.4.2 Europe Microbial Therapeutic Product Revenue by Application (2027-2032)
  9. 9.5 Europe Microbial Therapeutic Product Revenue Share by Application (2021-2032)
  10. 9.6 Europe Microbial Therapeutic Product Revenue by Country
  11. 9.6.1 Europe Microbial Therapeutic Product Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Microbial Therapeutic Product Revenue by Country (2021-2026)
  13. 9.6.3 Europe Microbial Therapeutic Product Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Microbial Therapeutic Product Revenue (2021-2032)
  2. 10.2 China Microbial Therapeutic Product Revenue by Type (2021-2032)
  3. 10.2.1 China Microbial Therapeutic Product Revenue by Type (2021-2026)
  4. 10.2.2 China Microbial Therapeutic Product Revenue by Type (2027-2032)
  5. 10.3 China Microbial Therapeutic Product Revenue Share by Type (2021-2032)
  6. 10.4 China Microbial Therapeutic Product Revenue by Application (2021-2032)
  7. 10.4.1 China Microbial Therapeutic Product Revenue by Application (2021-2026)
  8. 10.4.2 China Microbial Therapeutic Product Revenue by Application (2027-2032)
  9. 10.5 China Microbial Therapeutic Product Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Microbial Therapeutic Product Revenue (2021-2032)
  2. 11.2 Asia Microbial Therapeutic Product Revenue by Type (2021-2032)
  3. 11.2.1 Asia Microbial Therapeutic Product Revenue by Type (2021-2026)
  4. 11.2.2 Asia Microbial Therapeutic Product Revenue by Type (2027-2032)
  5. 11.3 Asia Microbial Therapeutic Product Revenue Share by Type (2021-2032)
  6. 11.4 Asia Microbial Therapeutic Product Revenue by Application (2021-2032)
  7. 11.4.1 Asia Microbial Therapeutic Product Revenue by Application (2021-2026)
  8. 11.4.2 Asia Microbial Therapeutic Product Revenue by Application (2027-2032)
  9. 11.5 Asia Microbial Therapeutic Product Revenue Share by Application (2021-2032)
  10. 11.6 Asia Microbial Therapeutic Product Revenue by Country
  11. 11.6.1 Asia Microbial Therapeutic Product Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Microbial Therapeutic Product Revenue by Country (2021-2026)
  13. 11.6.3 Asia Microbial Therapeutic Product Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Microbial Therapeutic Product Revenue (2021-2032)
  2. 12.2 SAMEA Microbial Therapeutic Product Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Microbial Therapeutic Product Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Microbial Therapeutic Product Revenue by Type (2027-2032)
  5. 12.3 SAMEA Microbial Therapeutic Product Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Microbial Therapeutic Product Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Microbial Therapeutic Product Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Microbial Therapeutic Product Revenue by Application (2027-2032)
  9. 12.5 SAMEA Microbial Therapeutic Product Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Microbial Therapeutic Product Revenue by Country
  11. 12.6.1 SAMEA Microbial Therapeutic Product Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Microbial Therapeutic Product Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Microbial Therapeutic Product Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst